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The nucleocapsid (N) protein of SARS-coronavirus (SARS-CoV) is the key protein for the formation of the helical nucleocapsid during
virion assembly. This protein is believed to be more conserved than other proteins of the virus, such as spike and membrane glycoprotein. In
this study, the N protein of SARS-CoV was expressed in Escherichia coli DH5a and identified with pooled sera from patients in the
convalescence phase of SARS. A plasmid pCI-N, encoding the full-length N gene of SARS-CoV, was constructed. Expression of the N
protein was observed in COS1 cells following transfection with pCI-N. The immune responses induced by intramuscular immunization with
pCI-N were evaluated in a murine model. Serum anti-N immunoglobulins and splenocytes proliferative responses against N protein were
observed in immunized BALB/c mice. The major immunoglobulin G subclass recognizing N protein was immunoglobulin G2a, and
stimulated splenocytes secreted high levels of gamma interferon and IL-2 in response to N protein. More importantly, the immunized mice
produced strong delayed-type hypersensitivity (DTH) and CD8+ CTL responses to N protein. The study shows that N protein of SARS-CoV
not only is an important B cell immunogen, but also can elicit broad-based cellular immune responses. The results indicate that the N protein
may be of potential value in vaccine development for specific prophylaxis and treatment against SARS.
D 2004 Elsevier Inc. All rights reserved.
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drome (SARS) has been associated with a novel coronavi-
rus, termed with SARS-Coronavirus (SARS-CoV), which
has strong infectivity and pathogenicity (Drosten et al.,
2003; Falsey et al., 2003; Ksiazek et al., 2003). Recently,
several new cases have been confirmed in Taiwan and
mainland of China, Singapore, and the Philippines. The
coronaviruses are large, enveloped positive-stranded RNA
viruses. The spike glycoprotein protein (S) forms conspic-
uous peplomer structures on the surface of the virus particle
and is responsible for many of the biological properties of
the virus, such as attachment to cell receptors, penetration,
and spread by virus-induced cell to cell fusion (Gagneten et0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.10.016
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E-mail address: qizt@smmu.edu.cn (Z.-T. Qi).al., 1995; Popova and Zhang, 2002; Sanchez et al., 1999;
Taguchi and Shimazaki, 2000). Antibodies to this protein
not only neutralize the virus in vitro, but also provide
protection against lethal virus challenge (Daniel and Talbot,
1990; Taguchi et al., 1995; Torres et al., 1995). Although the
S protein is the immunodominant structural component,
coronavirus infection also induces immune responses to
other structural proteins, such as the membrane glycoprotein
(M) and the nucleocapsid protein (N). The predicted N
protein of SARS-CoV is a highly charged, basic protein of
422 amino acids with seven successive hydrophobic
residues near the middle of the protein (Marra et al.,
2003; Rota et al., 2003). The cellular immune response
against N protein of some animal coronaviruses can enhance
the recovery from the virus infection (Glansbeek et al.,
2002; Wasmoen et al., 1995; Wesseling et al., 1993).05) 128–135
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antigens has provided protective immunity in some animal
models and is therefore considered a potentially useful
vaccine strategy (Fuller et al., 2002; Kamili et al., 2004;
Padua et al., 2003). This technique involves the transfer
of a target antigen gene into muscle cells by a plasmid
vector with subsequent endogenous production and
presentation for the induction of systemic immune
responses. In this aspect, DNA immunization appeared
to mimic natural viral infection. Hence, DNA vaccines
may provide a useful tool to dissect the immunogenicity
of a certain viral protein and define its roles in viral
immunity.
In the present study, the intact N protein of SARS-CoV
was expressed in Escherichia coli and its antigenicity was
analyzed with the pooled sera from convalescence phase of
SARS patients. Furthermore, a candidate DNA vaccine
containing the N gene was constructed and its immunoge-
nicity was evaluated in mice.Results
Expression of the N protein of SARS-CoV in E. coli and
identification of its antigenicity
The plasmid pHT-N encodes a fusion protein about
50 kDa with 6 histidines and other 25 amino acid residues at
its N-terminal. The bands of recombinant bacteria-expressed
N proteins could be visualized in SDS-PAGE as predicted.
There were two other proteins of smaller molecular mass
following purification with Ni-NTA affinity resin in addition
to the protein band corresponding to the complete fusion
protein (Fig. 1). Western blot analysis of the total bacterial
protein was carried out to determine the antigenicity of the
N protein. As shown in Fig. 1, all of the three proteins could
react with the pooled serum of SARS patients.Fig. 1. Expression of SARS-CoV N protein in E. coli DH5a. E. coli DH5awas tran
IPTG for induction of the SARS-CoV N protein expression, and the lysates of the b
DH5a culture without IPTG induction; Lane 2, E. coli DH5a culture with IPTG
Western blot analysis. Lane 1, E. coli DH5a culture without IPTG induction; LanExpression of N protein in COS1 cells
Intracellular expression of the N protein following
transfection with the pCI-N construct was evaluated in
COS1 cells by Western blot analysis. As shown in Fig. 2,
lysate of COS1 cells transfected with pCI-N could react with
the pooled serum of SARS patients, and the molecular mass
is consistent with 46 kDa of the whole N protein. The lysate
of COS1 cells transfected with control plasmid pCI-neo
could not develop the binding reaction.
Antibody response to SARS-CoV N protein in mice
Mouse sera were collected at weeks 0, 2, 4, 6, 8,
respectively (i.e., at 6 h prior to each of the three
immunizations and at weeks 2 and 4 after the last
immunization). The recombinant N protein-coated micro-
titer plates were used for detection of the total IgG and IgG
subclass antibodies by ELISA. For the DNA vaccine pCI-N
immunized mice, the specific antibodies were detectable
after the first boost, and the antibody positive rates were
33%, 75%, and 75% at weeks 4, 6, and 8, respectively. As
shown in Table 1, there is significant difference of ELISA
values between pCI-N immunized group and control group
after the first boost. The difference increases gradually
following the second boost. As shown in Table 2, the
increased level of IgG2a against the N protein was more
significant than that of IgG1 during the observation period.
Splenocyte proliferation and cytokine secretion assays
The splenocytes from DNA vaccine pCI-N immunized
mice responded significantly to the N protein in vitro while
they failed to respond to the unrelated antigen transferrin.
The splenocytes from control mice showed no response
either to N protein or transferrin. When stimulated with N
protein, the splenocytes from DNA vaccine immunizedsformed with the recombinant plasmid pHT-N and cultured with 0.6 mmol/L
acteria were prepared for analysis. (A) SDS-PAGE analysis. Lane 1, E. coli
induction; Lane 3, the purified N protein using Ni-NTA affinity resin. (B)
e 2, E. coli DH5a culture with IPTG induction.
Fig. 2. Expression of SARS-CoV N protein in transiently transfected COS1
cells. COS1 cells were transfected with recombinant plasmid pCI-N or pCI-
neo. After 48 h, the cells were lysed for Western blot analysis. Lane 1,
lysate of COS1 cells transfected with pCI-neo; Lane 2, lysate of COS1 cells
transfected with pCI-N.
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IL-10 compared with the control group. IFN-g and IL-2
levels were increased more than 10- to 30-fold, respectively.
IL-4 and IL-10 by stimulated splenocytes were also
increased 5- to 6-fold in animals inoculated with N protein
expression plasmid (Table 3).
DTH responses of mice
Four mice per group were subjected to detection of the
SARS-CoV N protein-specific DTH reaction using the
footpad swelling response at week 4 after the second boost.
The DNA vaccine pCI-N immunized mice developed
significant swelling, in which the difference of thickness
between the left and right footpads at 24 h after N protein
inoculation was 14.4 F 3.5  102 mm, while that of the
control plasmid immunized mice was only 3.3 F 1.4 
102 mm (P b 0.01). In fact, we found that the antibody
activity was not paralleled with the DTH response because
two antibody-negative mice also developed significant
footpad swelling.Table 1
Detection of IgG antibody against SARS-CoV N protein in sera of DNA immun
DNA construct Serum samples obtained at week
0 2
pCI-neo 0.08 F 0.03 0.10 F 0.02
pCI-N 0.09 F 0.03a 0.13 F 0.02b
BALB/c mice were immunized with 200 Ag of DNAvaccine pCI-N or control plasm
collected at weeks 0, 2, 4, 6, 8 post-immunization and detected for IgG against N
1:100 diluted serum samples F SD at various time courses. n = 12 mice.
a P N 0.5, compared with that of pCI-neo immunized group.
b P N 0.05, compared with that of pCI-neo immunized group.
c P b 0.01, compared with that of pCI-neo immunized group.
d P b 0.01, compared with that of pCI-neo immunized group.
e P b 0.001, compared with that of pCI-neo immunized group.Cytotoxic T lymphocyte response
To assess CTL activity in vitro, syngeneic BALB/c-
derived P815 mastocytoma cells were transfected with a
plasmid construct pcDNA3.1/Hygro-N. Western blot anal-
ysis showed that the selected clonal P815 cells stably
expressed the N protein of the SARS-CoV (data not
presented). The results illustrate the CTL activity exhibited
by splenocytes derived from pCI-N or mock plasmid
immunized mice at effector/target ratios of 25:1, 50:1, and
100:1 against the P815N04 cells expressing N protein
compared with native P815 target cells. As shown in Fig. 3,
the splenocytes from the mock plasmid immunized mice
showed no significant CTL killing activity against N protein
expressing P815 cells or parental P815 cells. It is note-
worthy that splenocytes from pCI-N immunized mice
specifically kill only the N protein expressing P815 cells.Discussion
The N protein of coronavirus binds to a defined pack-
aging signal on viral RNA, leading to the formation of the
helical nucleocapsid during virion assembly (Nguyen and
Hogue, 1997). In the present study, we found three kinds of
SARS-CoV N proteins with different molecular mass
expressed in E. coli and all of them could react with the
pooled sera from convalescence phase of SARS patients.
Two of the proteins with lower molecular mass may be
degraded from the amino terminus of the intact N fusion
protein since both could be purified by Ni-NTA affinity
resin (the six histidine residues are located at the amino
terminal of the fusion protein). In our observation, the N
protein is more sensitive to react with sera of SARS patients
relative to the S protein of SARS-CoV expressed in E. coli
(Zhao et al., 2004). This is consistent with those found in
some animal coronaviruses, indicating that the N protein
may be a sensitive antigen for SARS-CoV infection
(Wesseling et al., 1993). But it is still necessary to observe
its time course to evaluate the meaning for early diagnosis
of SARS-CoV infection.ized mice
4 6 8
0.12 F 0.02 0.13 F 0.02 0.14 F 0.03
0.22 F 0.08c 0.37 F 0.16d 0.43 F 0.17e
id pCI-neo three times at 2-week intervals. The mouse serum samples were
protein of SARS-CoV. The data are presented as mean value of ELISA of
Table 2
IgG subclasses against SARS-CoV N protein in DNA immunized mice
IgG subclasses Serum samples obtained at week
0 2 4 6 8
IgG2a 0.09 F 0.03 0.15 F 0.03 0.30 F 0.08 0.39 F 0.11 0.44 F 0.13
IgG1 0.09 F 0.02 0.11 F 0.02 0.16 F 0.04 0.20 F 0.05 0.21 F 0.07
BALB/c mice were immunized as described previously. The serum samples were assayed for IgG2a and IgG1 against N protein of SARS-CoV. The data are
presented as mean values of ELISA of 1:50 diluted serum samples F SD at various time courses; n = 12 mice.
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to express the N protein in eukaryotic cells, was used to
immunize BALB/c mice. The mouse serum anti-N antibody
response was detectable in the pCI-N immunized group
after the second immunization and continued to increase
after boosts. Seventy five percent of the mice developed
anti-N IgG antibody after three times of immunization. It is
unlikely that the antibodies against N protein play a
neutralizing role due to its internal position in the virion.
Some researchers reported that antibodies to N protein of
murine hepatitis virus (MHV, an animal coronavirus) had no
neutralizing activity in vitro, but a monoclonal antibody
(MAb) to the protein prevented the cytopathic effect of
MHV on L cells, and passive transfer of this antibody
protected mice from acute MHV infection (Lecomte et al.,
1987; Nakanaga et al., 1986). That whether the antibodies to
N protein of SARS-CoV have the similar protective effect in
vivo needs to be further investigated.
Cell-mediated immune response represents an important
defense mechanism against virus infection, which involved
cytotoxic T lymphocyte activity or T cell-derived antiviral
cytokines and so on (Altfeld et al., 2001; Eckels et al.,
2000). There is evident malfunction of cell immunity in
SARS patients, which may be one of the important
causative factors for this disease (Li et al., 2003). Therefore,
to enhance specific cellular immune response by vaccine
administration is likely to accelerate the clearance of the
virus and represents a potential alternative therapeutic
method against SARS. As an internal protein of SARS-
CoV, N protein is more conserved than surface protein such
as S or M proteins, which makes it an ideal candidate for
inclusion in a broadly protective vaccine for induction of
cellular immune response. It was reported that vaccination
with adenovirus vector expressing N protein of MHV could
protect a significant fraction of mice against a lethal
infection, which indicates that the N protein can generateTable 3
Splenocyte responses of mice immunized with DNA vaccine
DNA construct N Splenocyte stimulation index
N Protein Transferrin
pCI-neo 1.09 F 0.05 1.05 F 0.05
pCI-N 4.11 F 0.10 1.02 F 0.03
Splenocytes (2  106/well) obtained from different groups of immunized mice w
well flat-bottomed microtiter plates in a final volume of 200 Al. Cell-free super
standard ELISA kits and the splenocyte stimulation index was detected. Data rep
two is shown.a protective immune response (Wasmoen et al., 1995;
Wesseling et al., 1993). Splenic lymphocytes derived from
plasmid pCI-N inoculated mice stimulated with recombinant
N protein in vitro demonstrated significant proliferative
responses, whereas the mice failed to respond to a control
antigen transferrin.
It is known that subsets of Th cells can be distinguished
by the pattern of cytokines that they produce. Th1 cells
produce IFN-g, IL-2, and lymphotoxin and play a critical
role in directing cell-mediated immune responses, which are
important for clearance of intracellular pathogens. Th2 cells
produce IL-4, IL-5, IL-10, and IL-13, which are important
for humoral responses (Gor et al., 2003; Maldonado-Lopez
and Moser, 2001; Mosmann, 1992). To distinguish the
activation between Th1 and Th2 subsets, profiles of
cytokines released by N-stimulated splenocytes were
examined. Immunization of mice with plasmids pCI-N
resulted in a significant increase in Th1 cytokine production.
IFN-g and IL-2 levels were increased more than 10- to 30-
fold, respectively. The production of the Th2 cytokine IL-4
and IL-10 by stimulated splenocytes was also increased 5-
to 6-fold in animals inoculated with N protein expression
plasmid. These results indicated that the expression of N
protein by DNA vaccine activated both Th1 and Th2
subsets, although the activation level of Th1 subset was
much more significant. The results were agreeable with the
tendency of elevated IgG2a antibody against N protein in
murine sera.
An important natural mechanism for elimination of virus
in vivo is an antigen-specific cell-mediated immunity
(CMI). CD8+ T cells recognize viral antigens in the form
of short peptides presented by MHC class I molecules on
the surface of virus-infected cells. The recognition of these
viral peptides in the context of MHC molecules by CD8+ T
cells can trigger the specific lysis of virally infected cells
(Kagi et al., 1995) or noncytopathic intracellular inactiva-Amount of cytokine produced (pg/ml)
IFN-g IL-2 IL-4 IL-10
30 F 3 11 F 3 24 F 3 10 F 3
368 F 15 349 F 11 152 F 9 47 F 6
ere cultured in presence of N protein (3 Ag) or transferrin (20 Ag) in 96-
natants were harvested after 72 h and cytokine levels were measured by
resent means F SD of triplicate cultures. One representative experiment of
Fig. 3. CTL responses of BALB/c mice immunized with the DNA vaccine.
Mice were injected with DNA vaccine for three times. Single spleen cell
suspensions were assayed after in vitro stimulation with SARS-CoV N
protein-expressing P815 cells (P815N04) for 6 days. The effector cells were
then tested against target P815N04 (x) and parental P815 cells (n) in a
51Cr-release assay at the E/T ratios indicated. Values are means of triplicate
determinations. The effector cells were from pCI-N immunized mice (left
panel) or control plasmid pCI-neo immunized mice (right panel).
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interferon and tumor necrosis factor a (Guidotti and
Chisari, 2000; Mosmann et al., 1997). CD8+ CTL has thus
been implicated as playing a role in recovery or clearance
of virus during animal coronavirus and SARS-CoV
infection (Castro and Perlman, 1996; Glass and Lane,
2003; Wang and Chen, 2004).
The mice immunized with plasmid pCI-N developed
significant footpad swelling responses compared with the
control plasmid immunized mice. More importantly, gen-
eration of DTH activity occurred independent of anti-N
antibodies, which suggests that CD8+ T cell activation may
be induced by N protein without a coexisting humoral
immune response. The four test mice all developed
significant DTH response although two of them failed to
produce obvious anti-N antibody. Using the syngeneic
BALB/c-derived P815 mastocytoma cells that stably
express SARS-CoV N protein as target cells, we observed
that the splenocytes from pCI-N immunized mice showed
significant CTL activity, which could kill the N protein-
expressing target efficiently, but could not kill the native
P815 target cells. Our data on the DTH reaction assessed
using footpad swelling and results of the CTL assay clearly
demonstrated that SARS-CoV-specific CMI was elicited by
the DNA construct pCI-N. Recently, the cytotoxic T
lymphocyte response targeted to SARS-CoV N protein by
DNA immunization was also reported by Zhu et al. (2004)
and Kim et al. (2004). Together with our findings, we
believe that the N protein of SARS-CoV is an important
immunogen for T lymphocytes and may play a concernful
role in immunity-mediated virus elimination.
The N protein of transmissible gastroenteritis coronavirus
(TGEV) could accelerate the synthesis of neutralizingantibodies when porcine TGEV-immune cells were stimu-
lated with the combinations of S and N protein in vitro, and
the reason was referred to the helper T lymphocyte response
to the N protein (Anton et al., 1996). Gao et al. (2003)
reported that adenoviral delivery of SARS-CoV spike
protein S1 fragment, membrane protein, and N protein
could induce virus-specific broad immunity in rhesus
macaques, and all animals receiving intramuscular injec-
tions of recombinant adenovirus vaccine showed N-specific
T-cell response and strong neutralizing antibody responses
to SARS-CoV infection in vitro. From these data, we think
that the cellular immune response to the SARS-CoV N
protein may contribute to the induction of the neutralizing
antibodies, such as the antibodies against the spike protein
of the SARS-CoV.
In summary, our results demonstrate that the N protein of
SARS-CoV is of strong antigenicity to humans, and DNA
vaccination of N protein can induce both humoral and
cellular immune responses in mouse. These findings suggest
that the N protein should be a useful antigen candidate in the
development of SARS vaccines for the specific prophylaxis
of SARS-CoV infection.Materials and methods
Construction of prokaryotic expression plasmid for N gene
of SARS-CoV
The full-length N gene (1266 bp in length) of SARS-
CoV was synthesized according to the published sequence
(GenBank accession number: AY278554) and inserted into
the plasmid pUC18. The plasmid containing the N gene was
used as the template to amplify the DNA fragment for
construction of the prokaryotic expression plasmid using the
following primers: NF: 5V-GCTAGCGGATCCACCATGT-
CTGATAATGGACCCCAATC-3V; and NR: 5V-gaattcTTA-
TGCCTGAGTTGAATCAGCAG-3V. The amplified DNA
was transferred into pMD-18T vector (TaKaRA) using TA-
cloning and the correct sequence was verified. The
recombinant plasmid pHT-N was constructed by subcloning
the N gene into the prokaryotic expression plasmid pProEX
HTa (Life Technologies) at its BamHI–EcoRI site.
Expression and identification of the N protein of SARS-CoV
The recombinant plasmid pHT-N was transformed into
E. coli DH5a for expression of the N protein. A fresh
transformant was incubated overnight in liquid LB
medium containing 100 mg/L ampicillin. The culture
was diluted with 2YT medium at 1% of volume, and
incubated at 37 8C until A600 reached 0.6 absorbance
units. Then IPTG was added at a final concentration of
0.6 mmol/L for the induction of N protein expression. The
cultured bacteria were collected after 3 h and subjected to
SDS-PAGE and Western blot analyses. Serum antibodies
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SARS patients in Beijing Xiaotangshan Hospital, and
inactivated by incubation at 56 8C for 30 min. The patient
sera were pooled, and used as the primary antibody in
Western blot, while the horseradish peroxidase (HRP)
conjugated goat-anti-human IgG (Sigma) was used as the
secondary antibody.
The expressed N protein was purified using Ni-NTA
affinity resin (Qiagen) according to the manufacturer’s
directions. The purified N protein was further treated with
Detoxi-Gel Endotoxin Removing Gel (PIERCE, Rockford)
and tested by the Limulus amebocyte lysate assay (Sigma)
to ensure that it was free of endotoxin contamination (below
detection level b0.1 EU/mL).
Construction of DNA vaccine containing SARS-CoV N gene
The recombinant plasmid pMD18-T containing the full-
length N gene was digested with NheI and EcoRI. Then, the
N gene fragment was isolated and inserted into the
eukaryotic expression plasmid pCI-neo (Promega) at
NheI–EcoRI site. The recombinant plasmid pCI-N was
served as DNA vaccine candidate for the further use.
Expression of SARS-CoV N protein in COS1 cells
COS1 cells were grown in DMEM medium (Gibco-BRL)
supplemented with 10% heat-inactivated fetal bovine serum,
100 U/mL of penicillin, and 100 Ag/mL streptomycin sulfate
at 5% CO2. The recombinant plasmid pCI-N and control
vector pCI-neo were transfected into COS1 cells using
Lifectamine reagent (Gibco-BRL) according to the manu-
facturer’s instructions, respectively. Logarithmically growing
cells in 35 mm dishes were transfected with 1 Ag of plasmid
and 10 Al of Lifectamine reagent. At 48 h after transfection,
the cells were washed twice with ice-cold PBS and lysed in
1SDS lysis buffer (50 mM Tris (pH 6.8), 50 mM DTT, 2%
SDS, 10% glycerol, 100 Ag/mL PMSF, 10 Ag/mL leupeptin
and 0.1% bromophenol blue) for 10 min on ice. Cell lysates
were boiled and centrifugated at 12 000  g at 4 8C for
10 min. The supernatants were collected and subjected to
Western blot analysis.
DNA immunization of mice
The vaccine candidate pCI-N and control vector pCI-neo
were prepared using Qiagen MegaPrep columns (Qiagen).
The DNA plasmid was mixed with 3.4% polyvinyl
pyrrolidone (PVP, MW 40,000, Sigma) in 0.01 M PBS to
a final concentration of 2 g/L for immunization of mice.
When used in DNA vaccine formulations, PVP binds to
DNA, which facilitates uptake by skin and muscle cells
(Alila et al., 1997; Anwer et al., 1998). Six-week-old female
BALB/c mice (Xiper-Bikai Experimental Animal Co., LTD,
Shanghai) were randomly divided into two groups (12 mice
per group). The mice in experimental group were injectedwith 200 Ag of pCI-N in both tibialis anterior muscles three
times at 2-week intervals. The mice in control group
received the same amount of the vector pCI-neo in identical
route and frequency.
Antibody measurement
Microtiter plates were coated with purified N protein at
concentration of 50 mg/L in carbonate buffer. After 4 8C
overnight, the coated plates were blocked with 5% nonfat
dry milk in PBS. The plates were then used for the detection
of the antibody against N protein of SARS-CoV in mice.
Mouse sera were collected by retroorbital bleeding and kept
in 70 8C. The serum samples were serially diluted with
0.01 M PBS containing 12% goat sera and 0.5% Tween-20
prior to antibody detection. The serum antibody was
captured by the coated N protein, and detected by
1:10000 diluted HRP conjugated goat-anti-mouse IgG
(Sigma). Color was developed with 3,3V,5,5V-tetramethylben-
zidine (TMB) substrate, and the absorbance at 450 nm
(A450) was measured. It was considered positive when the
A450 value of the mouse serum from experimental group is
over or equal to 2.1-time of mean value of the mouse serum
from the control group.
A similar protocol was followed for ELISA assessing IgG
subclass. Sera from individual mice were 1:50 diluted for
detection of IgG2a and IgG1. The HRP-conjugated goat-anti-
mouse IgG2a and IgG1 were used as secondary antibodies
(SouthernBiotech).
Splenocyte proliferation assay
Four mice per group were sacrificed at week 4 after
the last immunization. Spleens were isolated and ground
between the frosted ends of two glass microscope slides.
The cell suspension was then passed through a fine nylon
mesh to obtain a single cell suspension. Erythrocytes
were lysed by incubation in 0.84% NH4Cl solution.
Splenocytes were cultured in triplicate in 96-well flat-
bottomed plates at 2  106 cells per well in 200 Al
RPMI 1640 containing 10% heat-inactivated fetal bovine
serum. Stimulated cells received purified N protein at a
final concentration of 15 Ag/mL or transferrin (Sigma) at
100 Ag/mL, while the control cells received no additional
protein stimulation. The plates were incubated at 37 8C
in 5% CO2 for 72 h. Following stimulation, 100 Al of
culture supernatant was collected from each well for
subsequent cytokine analyses. The splenocyte prolifera-
tion of each well was measured by the tetrazolium
compound, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium),
and phenazine ethosulfate (PES) according to the
manufacturer’s suggestions (Promega) (Mahon et al.,
2003). The stimulation index was defined as the ratio
of the mean absorbance at 490 nm per well of the
stimulated cells and control cells.
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Splenocyte proliferation assays were carried out as
described above. The supernatants of splenocyte culture
were harvested and subjected to measurement for IFN-g, IL-
2, IL-4, and IL-10 with ELISA detection systems (Pharmin-
gen) (Pertmer et al., 1996). In brief, the microtiter plates
coated with rat anti-mouse IFN-g, IL-2, IL-4, or IL-10 were
incubated with duplicates of serially diluted samples and
standards overnight at 4 8C. Plates were then washed and
biotinylated secondary antibodies specific for murine IFN-g,
IL-2, IL-4, or IL-10 at 2 Ag/mL were added to each well.
After 45 min at 37 8C, plates were washed and avidin-
phosphatase (1/500 dilution; Pharmingen) was added at
100 Al per well. After 30 min at room temperature, the
plates were washed again. The color was developed with
p-nitrophenyl phosphate (Sigma) as the substrate, and the
absorbance at 405 nm was measured. The concentrations of
cytokines in the supernatants were determined from the
standard curve.
Detection of delayed-type hypersensitivity(DTH)response
The DTH response was assessed by a footpad swelling
method (Eaton et al., 2001; Shibata et al., 2001). At week 4
after the last immunization, a total of 25 Al PBS containing
10 Ag of recombinant N protein was injected into the left
footpad of the mice in both experimental and control groups.
The right footpad received sterile PBS as control. After 24 h,
the mice were euthanized and footpad swelling was
measured with a spring-loaded metric caliper. Left footpad
thickness minus right footpad thickness was calculated.
Cytotoxic cell assay
The SARS-CoV N gene sequence was removed from the
plasmid pCI-N by NheI–XbaI digestion, and inserted into an
expression vector pcDNA3.1/Hygro(+) with hygromycin as
selectable marker (Invitrogen). The resulting plasmid
pcDNA3.1/Hygro-N was transfected into P815 cells and
the stable transfectants were selected by hygromycin. A
hygromycin-resistant cell clone P815N04, which was
proved to be able to express endogenously SARS-CoV N
protein by Western blot analysis (data not shown), was used
for the CTL assays.
The CTL activity was determined by a standard 51Cr-
release assay (Uger and Barber, 1997). Spleen cells from
immunized mice were suspended in complete DMEM
containing 10% FCS and 50 AM 2-mercaptoethanol and
analyzed for cytotoxic activity 5 days after in vitro
stimulation. Recombinant murine IL-2 was added once at
day 2 at a concentration of 10 U/mL, and responded cells
(5  107) were cocultured with 1  107 irradiated syngeneic
cells P815 N04 (8000 rad) stably expressing the N protein.
Cytotoxic effector lymphocyte populations were harvested
after 6 days of incubation. A 5-h 51Cr-release assay wasperformed in a 96-well round-bottomed plate using as target
cell lines 51Cr-labeled P815N04 or parental P815 cells. CTL
assays were performed at lymphocyte effector/target (E/T)
ratios of 100:1, 50:1, 25:1. The amount of 51Cr released was
determined by gamma counting and the specific lysis was
calculated according to the following formula: percentage
specific lysis = (experiment release  spontaneous release) /
(maximum release  spontaneous release). Experimental
release represents the mean counts per minute released by
target cells in the presence of effector cells. Total release
represents the radioactivity released after total lysis of target
cells with 5% Triton X-100. Spontaneous release represents
the radioactivity present in medium derived from target cells
only.
Statistical analysis
Data obtained were analyzed for statistical significance
by Student’s t test. P b 0.05 was considered significant.Acknowledgments
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